Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Deferred Revenue (2016)

Historic Current Deferred Revenue for Anaptysbio (ANAB) over the last 3 years, with Q4 2016 value amounting to -$2.9 million.

  • Anaptysbio's Current Deferred Revenue fell 20000.0% to -$2.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$2.9 million, marking a year-over-year decrease of 20000.0%. This contributed to the annual value of -$2.9 million for FY2016, which is 20000.0% down from last year.
  • As of Q4 2016, Anaptysbio's Current Deferred Revenue stood at -$2.9 million, which was down 20000.0% from $2.9 million recorded in Q4 2015.
  • Anaptysbio's 5-year Current Deferred Revenue high stood at $10.7 million for Q4 2014, and its period low was -$2.9 million during Q4 2016.
  • For the 3-year period, Anaptysbio's Current Deferred Revenue averaged around $3.6 million, with its median value being $2.9 million (2015).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 7258.15% in 2015, then crashed by 20000.0% in 2016.
  • Quarter analysis of 3 years shows Anaptysbio's Current Deferred Revenue stood at $10.7 million in 2014, then plummeted by 72.58% to $2.9 million in 2015, then tumbled by 200.0% to -$2.9 million in 2016.
  • Its Current Deferred Revenue stands at -$2.9 million for Q4 2016, versus $2.9 million for Q4 2015 and $10.7 million for Q4 2014.